We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hypermethylated Genes Involved in Cancer Development

By Biotechdaily staff writers
Posted on 25 Feb 2003
Cancer researchers have found that loss of the hypermethylated-in-cancer 1 gene (Hic1), which encodes a zinc-finger transcription factor but fails to function in several types of human cancer, induces gender-linked development of cancers in a mouse model. More...
Their findings were published in the February 2003 issue of Nature Genetics.

Investigators from Johns Hopkins University's Kimmel Cancer Center (Baltimore, MD, USA; www.jhu.edu) genetically engineered a line of mice that lacked one copy of the Hic1 gene. Mice completely lacking the gene failed to develop past the embryo stage.

When the modified mice were more than 70 weeks old, excessive cancers begin to emerge. By 90 weeks of age, 16.4% of the experimental mice had developed tumors, while no normal mice had. By 100 weeks, experimental mice had almost three times the rate of tumors as normal mice (34.2 % versus 14.3% of normal mice). The kind of tumors that appeared depended on the mouse's sex. Female mice tended to develop lymphomas and sarcomas, while male mice developed more epithelial cancers.

"Most genes linked to cancer were first identified from mutations in families, and subsequently some of the same genes were found to be hypermethylated, but Hic1 was identified solely because of extra methylation in cancer cells,” explained senior author Dr. Stephen Baylin, professor in the cancer biology division of John Hopkins University. "Now we have shown directly that loss of the gene's function leads to cancers in mice.”

Whether the gender effects seen in mice are present in human cancers remains to be learned.



Related Links:
Johns Hopkins University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.